DISEASES CAUSED BY CAMPYLOBACTER JEJUNI, THE RELEVANCE OF THEIR DETECTION AND TREATMENT

Authors

  • Karima Abdurakhmonova Assistant of the Department of Microbiology, Virusology and Immunology of Tashkent State Medical University, Tashkent, Uzbekistan.
  • Sayyod Ergashboev Student of the 2nd Faculty of General Medicine of Tashkent State Medical University, Tashkent, Uzbekistan.
  • Mansur Abdisoatov Student of the 2nd Faculty of General Medicine of Tashkent State Medical University, Tashkent, Uzbekistan.
  • Muattarkhon Nazirova Student of the 2nd Faculty of General Medicine of Tashkent State Medical University, Tashkent, Uzbekistan.

Keywords:

Campylobacter jejuni, probiotics, phytochemicals, bacteriophages, gut microbiota, epithelial barrier, One Health, and vaccines

Abstract

A common zoonotic bacterium that commensally colonizes the guts of numerous bird species is Campylobacter jejuni. C. jejuni is a significant foodborne pathogen in humans. Human infection results in small intestinal campylobacteriosis, which is the primary cause of bacteria-dependent gastroenteritis cases globally. The majority of C. jejuni infections are specifically caused by consuming undercooked rooster meat, raw milk, contaminated water, and cross-contamination of ready-to-eat food after handling raw chicken meat. The Guillain-Barré, Miller Fisher, and Reiter syndromes are among the post-infection disorders of the nervous system and joints that infected people may later experience along with watery and/or bloody diarrhea accompanied by stomach pain. Reducing C. jejuni colonization in poultry farms using vaccination, bacteriocins, and phage therapy procedures is one therapeutic approach. Following strict hygienic guidelines is one of the preventative measures used during the production of poultry meat. Additionally, employing well-established mice and in vitro cell model systems, significant advancements have been made recently in the fight against campylobacteriosis. In this sense, particular elements linked to C. jejuni colonization and pathogenicity were regarded as preferred treatment structures, focusing on bacterial mobility, host cell interaction, intracellular survival, and bacterial multiplication and spread. In order to lessen C. jejuni-induced epithelial cell damage, inflammation, and apoptosis in infected mice, several pharmacological substances have been added to this. In order to lessen the effects of acute campylobacteriosis and post-infection sequelae in humans, we examine these innovative treatment and preventative strategies as well as "One World-One Health" initiatives.

References

Fischer GH, Hashmi MF, Paterek E. Campylobacter Infection. [Updated 2024 Jan 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537033/

Sharafutdinov I, Linz B, Tegtmeyer N, Backert S. Therapeutic and protective approaches to combat Campylobacter jejuni infections. Front Pharmacol. 2025 May 6;16:1572616. doi: 10.3389/fphar.2025.1572616.

Veronese P, Dodi I. Campylobacter jejuni/coli Infection: Is It Still a Concern? Microorganisms. 2024; 12(12):2669. https://doi.org/10.3390/microorganisms12122669

Ahmed N. A., Gulhan T. (2022). Campylobacter in wild birds: is it an animal and public health concern? Front. Microbiol. 12, 812591. 10.3389/fmicb.2021.812591

Alter T., Reich F. (2021). Management strategies for prevention of Campylobacter infections through the poultry food chain: a European perspective. Curr. Top. Microbiol. Immunol. 431, 79–102. 10.1007/978-3-030-65481-8_4

Alvarez-Martínez F., Barrajón-Catalán E., Herranz-López M., Micol V. (2021). Antibacterial plant compounds, extracts and essential oils: an updated review on their effects and putative mechanisms of action. Phytomedicine 90, 153626. 10.1016/j.phymed.2021.153626

Balta I., Butucel E., Stef L., Pet I., Gradisteanu-Pircalabioru G., Chifiriuc C., et al. (2022). Anti-Campylobacter probiotics: latest mechanistic insights. Foodborne Pathog. Dis. 19, 693–703. 10.1089/fpd.2022.0039

Balta I., Linton M., Pinkerton L., Kelly C., Stef L., Pet I., et al. (2021c). The effect of natural antimicrobials against Campylobacter spp. and its similarities to Salmonella spp., Listeria spp., Escherichia coli, Vibrio spp., Clostridium spp. and Staphylococcus spp. Food control. 121, 107745. 10.1016/j.foodcont.2020.107745

Bandick R., Busmann L., Mousavi S., Shayya N., Piwowarski J., Granica S., et al. (2023). Therapeutic effects of oral application of menthol and extracts from tormentil (Potentilla erecta), raspberry leaves (Rubus idaeus), and loosestrife (Lythrum salicaria) during acute murine campylobacteriosis. Pharmaceutics 15 (10), 2410. 10.3390/pharmaceutics15102410

Du K., Bereswill S., Heimesaat M. (2021). A literature survey on antimicrobial and immune-modulatory effects of butyrate revealing non-antibiotic approaches to tackle bacterial infections. Eur. J. Microbiol. Immunol. (Bp) 11 (1), 1–9. 10.1556/1886.2021.00001

Du K., Foote M., Mousavi S., Buczkowski A., Schmidt S., Bereswill S., et al. (2022). Less pronounced immunopathological responses following oral butyrate treatment of Campylobacter jejuni-infected mice. Microorganisms 10 (10), 1953. 10.3390/microorganisms10101953

Du K., Foote M., Mousavi S., Buczkowski A., Schmidt S., Peh E., et al. (2023). Combination of organic acids benzoate, butyrate, caprylate, and sorbate provides a novel antibiotics-independent treatment option in the combat of acute campylobacteriosis. Front. Microbiol. 14, 1128500. eCollection 2023. 10.3389/fmicb.2023.1128500

Du K., Mousavi S., Foote M., Bereswill S., Heimesaat M. (2024). Therapeutic effects of oral benzoic acid application during acute murine campylobacteriosis. Eur. J. Microbiol. Immunol. (Bp) 14 (3), 243–260. 10.1556/1886.2024.00059

Heimesaat M. M., Schmidt A. M., Mousavi S., Escher U., Tegtmeyer N., Wessler S., et al. (2020a). Peptidase PepP is a novel virulence factor of Campylobacter jejuni contributing to murine campylobacteriosis. Gut Microbes 12, 1770017. 10.1080/19490976.2020.1770017

Jansen L., Birn R., Koirala S., Oppegard S., Loeck B., Hamik J., et al. (2024). Campylobacteriosis outbreak linked to municipal water, Nebraska, USA, 20211. Emerg. Infect. Dis. 30, 1998–2005. 10.3201/eid3010.231509

Jimenez B., Awwad F., Desgagné-Penix I. (2024). Cinnamaldehyde in focus: antimicrobial properties, biosynthetic pathway, and industrial applications. Antibiotics 13 (11), 1095. 10.3390/antibiotics13111095

Jin X., He Y., Zhou Y., Chen X., Lee Y., Zhao J., et al. (2021). Lactic acid bacteria that activate immune gene expression in Caenorhabditis elegans can antagonise Campylobacter jejuni infection in nematodes, chickens and mice. BMC Microbiol. 21 (1), 169. 10.1186/s12866-021-02226-x

Katz, A.; Porte, L.; Weitzel, T.; Varela, C.; Muñoz-Rehbein, C.; Ugalde, J.A.; Grim, C.; González-Escalona, N.; Blondel, C.J.; Bravo, V. Whole-Genome Sequencing Reveals Changes in Genomic Diversity and Distinctive Repertoires of T3SS and T6SS Effector Candidates in Chilean Clinical Campylobacter Strains. Front. Cell. Infect. Microbiol. 2023, 13, 1208825

Monteiro, M.A.; Chen, Y.-H.; Ma, Z.; Ewing, C.P.; Mohamad Nor, N.; Omari, E.; Song, E.; Gabryelski, P.; Guerry, P.; Poly, F. Relationships of Capsular Polysaccharides Belonging to Campylobacter Jejuni HS1 Serotype Complex. PLoS ONE 2021, 16, e0247305.

Konkel, M.E.; Talukdar, P.K.; Negretti, N.M.; Klappenbach, C.M. Taking Control: Campylobacter Jejuni Binding to Fibronectin Sets the Stage for Cellular Adherence and Invasion. Front. Microbiol. 2020, 11, 564.

Kirk, K.F.; Boel, J.; Nielsen, H.L. Vertebral Osteomyelitis Caused by Campylobacter Jejuni in an Immunocompetent Patient. Gut Pathog. 2023, 15, 61.

Shahrizaila, N.; Lehmann, H.C.; Kuwabara, S. Guillain-Barré Syndrome. Lancet 2021, 397, 1214–1228.

Leonhard, S.E.; van der Eijk, A.A.; Andersen, H.; Antonini, G.; Arends, S.; Attarian, S.; Barroso, F.A.; Bateman, K.J.; Batstra, M.R.; Benedetti, L.; et al. An International Perspective on Preceding Infections in Guillain-Barré Syndrome. Neurology 2022, 99, e1299–e1313.

Worku M, Tessema B, Ferede G, Ochieng L, Leliso SA, Mutua F, Moodley A, Grace D, Gelaw B. Campylobacter jejuni and Campylobacter coli infection, determinants and antimicrobial resistance patterns among under-five children with diarrhea in Amhara National Regional State, Northwest Ethiopia. PLoS One. 2024 Jul 3;19(7):e0304409. doi: 10.1371/journal.pone.0304409.

Diriba, K.; Awulachew, E.; Anja, A. Prevalence and Associated Factor of Campylobacter Species among Less than 5-Year-Old Children in Ethiopia: A Systematic Review and Meta-Analysis. Eur. J. Med. Res. 2021, 26, 2.

Tabata, H.; Horinishi, Y.; Sano, C. A Case of Pseudoappendicitis Caused by Campylobacter Enteritis Diagnosed by Gram Staining and Direct Microscopic Investigation of Stool Specimen. Cureus 2023, 15, e33980.

Dai, L.; Sahin, O.; Grover, M.; Zhang, Q. New and Alternative Strategies for the Prevention, Control, and Treatment of Antibiotic-Resistant Campylobacter. Transl. Res. 2020, 223, 76–88.

Downloads

Published

2026-05-05